1
|
Barbalho SM, Direito R, Laurindo LF, Marton LT, Guiguer EL, Goulart RDA, Tofano RJ, Carvalho ACA, Flato UAP, Capelluppi Tofano VA, Detregiachi CRP, Bueno PCS, Girio RSJ, Araújo AC. Ginkgo biloba in the Aging Process: A Narrative Review. Antioxidants (Basel) 2022; 11:525. [PMID: 35326176 PMCID: PMC8944638 DOI: 10.3390/antiox11030525] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 03/03/2022] [Accepted: 03/05/2022] [Indexed: 02/04/2023] Open
Abstract
Neurodegenerative diseases, cardiovascular disease (CVD), hypertension, insulin resistance, cancer, and other degenerative processes commonly appear with aging. Ginkgo biloba (GB) is associated with several health benefits, including memory and cognitive improvement, in Alzheimer's disease (AD), Parkinson's disease (PD), and cancer. Its antiapoptotic, antioxidant, and anti-inflammatory actions have effects on cognition and other conditions associated with aging-related processes, such as insulin resistance, hypertension, and cardiovascular conditions. The aim of this study was to perform a narrative review of the effects of GB in some age-related conditions, such as neurodegenerative diseases, CVD, and cancer. PubMed, Cochrane, and Embase databases were searched, and the PRISMA guidelines were applied. Fourteen clinical trials were selected; the studies showed that GB can improve memory, cognition, memory scores, psychopathology, and the quality of life of patients. Moreover, it can improve cerebral blood flow supply, executive function, attention/concentration, non-verbal memory, and mood, and decrease stress, fasting serum glucose, glycated hemoglobin, insulin levels, body mass index, waist circumference, biomarkers of oxidative stress, the stability and progression of atherosclerotic plaques, and inflammation. Therefore, it is possible to conclude that the use of GB can provide benefits in the prevention and treatment of aging-related conditions.
Collapse
Affiliation(s)
- Sandra Maria Barbalho
- Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marília (UNIMAR), Marília 17525-902, SP, Brazil; (E.L.G.); (R.d.A.G.); (R.J.T.); (A.C.A.C.); (U.A.P.F.); (C.R.P.D.); (P.C.S.B.); (A.C.A.)
- Department of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17525-902, SP, Brazil; (L.F.L.); (L.T.M.); (V.A.C.T.)
- School of Food and Technology of Marilia (FATEC), Avenida Castro Alves, Marília 17500-000, SP, Brazil
| | - Rosa Direito
- Laboratory of Systems Integration Pharmacology, Clinical & Regulatory Science, Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal;
| | - Lucas Fornari Laurindo
- Department of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17525-902, SP, Brazil; (L.F.L.); (L.T.M.); (V.A.C.T.)
| | - Ledyane Taynara Marton
- Department of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17525-902, SP, Brazil; (L.F.L.); (L.T.M.); (V.A.C.T.)
| | - Elen Landgraf Guiguer
- Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marília (UNIMAR), Marília 17525-902, SP, Brazil; (E.L.G.); (R.d.A.G.); (R.J.T.); (A.C.A.C.); (U.A.P.F.); (C.R.P.D.); (P.C.S.B.); (A.C.A.)
- Department of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17525-902, SP, Brazil; (L.F.L.); (L.T.M.); (V.A.C.T.)
- School of Food and Technology of Marilia (FATEC), Avenida Castro Alves, Marília 17500-000, SP, Brazil
| | - Ricardo de Alvares Goulart
- Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marília (UNIMAR), Marília 17525-902, SP, Brazil; (E.L.G.); (R.d.A.G.); (R.J.T.); (A.C.A.C.); (U.A.P.F.); (C.R.P.D.); (P.C.S.B.); (A.C.A.)
| | - Ricardo José Tofano
- Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marília (UNIMAR), Marília 17525-902, SP, Brazil; (E.L.G.); (R.d.A.G.); (R.J.T.); (A.C.A.C.); (U.A.P.F.); (C.R.P.D.); (P.C.S.B.); (A.C.A.)
- Department of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17525-902, SP, Brazil; (L.F.L.); (L.T.M.); (V.A.C.T.)
| | - Antonely C. A. Carvalho
- Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marília (UNIMAR), Marília 17525-902, SP, Brazil; (E.L.G.); (R.d.A.G.); (R.J.T.); (A.C.A.C.); (U.A.P.F.); (C.R.P.D.); (P.C.S.B.); (A.C.A.)
| | - Uri Adrian Prync Flato
- Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marília (UNIMAR), Marília 17525-902, SP, Brazil; (E.L.G.); (R.d.A.G.); (R.J.T.); (A.C.A.C.); (U.A.P.F.); (C.R.P.D.); (P.C.S.B.); (A.C.A.)
- Department of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17525-902, SP, Brazil; (L.F.L.); (L.T.M.); (V.A.C.T.)
| | - Viviane Alessandra Capelluppi Tofano
- Department of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17525-902, SP, Brazil; (L.F.L.); (L.T.M.); (V.A.C.T.)
| | - Cláudia Rucco Penteado Detregiachi
- Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marília (UNIMAR), Marília 17525-902, SP, Brazil; (E.L.G.); (R.d.A.G.); (R.J.T.); (A.C.A.C.); (U.A.P.F.); (C.R.P.D.); (P.C.S.B.); (A.C.A.)
| | - Patrícia C. Santos Bueno
- Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marília (UNIMAR), Marília 17525-902, SP, Brazil; (E.L.G.); (R.d.A.G.); (R.J.T.); (A.C.A.C.); (U.A.P.F.); (C.R.P.D.); (P.C.S.B.); (A.C.A.)
- Department of Animal Sciences, School of Veterinary Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho 1001, Marília 17525-902, SP, Brazil;
| | - Raul S. J. Girio
- Department of Animal Sciences, School of Veterinary Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho 1001, Marília 17525-902, SP, Brazil;
| | - Adriano Cressoni Araújo
- Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marília (UNIMAR), Marília 17525-902, SP, Brazil; (E.L.G.); (R.d.A.G.); (R.J.T.); (A.C.A.C.); (U.A.P.F.); (C.R.P.D.); (P.C.S.B.); (A.C.A.)
- Department of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17525-902, SP, Brazil; (L.F.L.); (L.T.M.); (V.A.C.T.)
| |
Collapse
|
2
|
Siegel G, Ermilov E, Knes O, Rodríguez M. Combined lowering of low grade systemic inflammation and insulin resistance in metabolic syndrome patients treated with Ginkgo biloba. Atherosclerosis 2014; 237:584-8. [PMID: 25463092 DOI: 10.1016/j.atherosclerosis.2014.10.023] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2014] [Revised: 09/25/2014] [Accepted: 10/16/2014] [Indexed: 10/24/2022]
Abstract
In a clinical pilot study with eleven metabolic syndrome patients, a simultaneous decrease in hs-CRP from 8.85 ± 4.09 to 4.92 ± 2.51 mg/L (-44.4%) (p < 0.0436) and HOMA-IR from 3.07 ± 0.63 to 2.60 ± 0.51 mU/L × mg/dL (-15.3%) (p < 0.0120) as well as a beneficial change of arteriosclerotic, inflammatory and oxidative stress biomarkers were detected after 2-month treatment with Ginkgo biloba. Furthermore, both IL-6 (-12.9%, p < 0.0407) and nanoplaque formation (-14.3%, p < 0.0077) were additionally reduced. According to a large clinical trial elucidating the importance of insulin resistance and low-grade systemic inflammation for cardiovascular disease and overall mortality risk, these data might indicate a CVD/total mortality risk reduction.
Collapse
Affiliation(s)
- G Siegel
- Charité - University Clinic Berlin, 10117 Berlin, Germany; University of Uppsala Biomedical Center, 751 23 Uppsala, Sweden.
| | - E Ermilov
- Charité - University Clinic Berlin, 10117 Berlin, Germany
| | - O Knes
- Swiss Analysis AG, 8274 Tägerwilen, Switzerland
| | - M Rodríguez
- Charité - University Clinic Berlin, 10117 Berlin, Germany; Scienion AG, 12489 Berlin, Germany
| |
Collapse
|